Filing Flows › Neuroone Medical Technologies (NMTC) › Q3 FY26
Neuroone Medical Technologies (NMTC) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 13, 2026
Neuroone Medical Technologies (NMTC) reported revenue of $2.0M for the third quarter fiscal 2026 (Q3 FY26), +16% from a year earlier and +6% from the quarter before. Operating margin was -122.9%, net loss $2.0M (101.7% of revenue).
Neuroone Medical Technologies, Q3 FY26: revenue $2.0M (+16% year over year), operating margin -122.9%, net loss $2.0M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | +6% | +16% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $2.0M in Q3 FY26, up 16% year over year and up 6% from the previous quarter.
Gross margin was 59.9%, up 6.0 points from Q3 FY25. Operating costs exceeded revenue by $2.4M, an operating margin of -122.9%. Operating expenses grew 29% against revenue growth of 16%. The fastest-growing cost line was SG&A (+35%). The quarter ended with a net loss of $2.0M, narrower than the previous quarter's $2.4M loss. Non-operating items added $418K, -21% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.1M. Non-cash charges added back $47K of depreciation and amortization and $353K of share-based compensation. Working capital and other items added $525K. Capital expenditures of $20K exceeded it, leaving free cash flow of −$1.1M.
Questions
What was Neuroone Medical Technologies' revenue in the third quarter fiscal 2026?
Neuroone Medical Technologies (NMTC) reported revenue of $2.0M for the third quarter fiscal 2026 (Q3 FY26), +16% from a year earlier and +6% from the quarter before.
Was Neuroone Medical Technologies profitable in the third quarter fiscal 2026?
Operating loss was $2.4M (-122.9% of revenue) and net loss $2.0M.